Keryx Biopharmaceuticals to Hold Conference Call Tomorrow at 8:00 AM ET to Discuss Top-Line Results from Zerenex Phase 3 Long-Term Study

Sun Jan 27, 2013 6:15pm EST

* Reuters is not responsible for the content in this press release.

For best results when printing this announcement, please click on the link
below:

http://pdf.reuters.com/pdfnews/pdfnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20130127:nPnNY48921




NEW YORK,  Jan. 27, 2013  /PRNewswire/ -- Keryx Biopharmaceuticals, Inc.
(NASDAQ: KERX) will host a conference call tomorrow,  Monday, January 28, at 
8:00am ET  to review the top-line results from the Phase 3 long-term study
component of its Phase 3 registration program of Zerenex™  (ferric citrate), the
Company's ferric iron-based phosphate binder for the treatment of elevated serum
phosphorus levels, or hyperphosphatemia, in patients with end-stage renal
disease on dialysis. Keryx will announce the top-line results tomorrow morning,
prior to the call.  

Ron Bentsur, Chief Executive Officer of Keryx, will host the call.  Dr.  Julia
Lewis, Professor of Medicine, Department of Nephrology,  Vanderbilt University 
School of Medicine, and member of the Executive Committee of the Collaborative
Study Group, and Study Chair of the Zerenex Phase 3 registration program, will
also join the call.  

In order to participate in the conference call, please call 1-877-869-3847
(U.S.), 1-201-689-8261 (outside the U.S.), call-in ID: KERYX. The rebroadcast of
the conference call will be available for replay at  http://www.keryx.com, for a
period of 15 days after the call.

About Keryx Biopharmaceuticals, Inc.  
Keryx Biopharmaceuticals is focused on the acquisition, development and
commercialization of medically important pharmaceutical products for the
treatment of renal disease. Keryx is developing Zerenex (ferric citrate), an
oral, ferric iron-based compound that has the capacity to bind to phosphate and
form non-absorbable complexes. The U.S.-based Phase 3 clinical program of
Zerenex for the treatment of hyperphosphatemia (elevated phosphate levels) in
patients with end-stage renal disease is being conducted pursuant to a Special
Protocol Assessment (SPA) agreement with the FDA. Zerenex is also in Phase 2
development for the management of phosphorus and iron deficiency in anemic
patients with Stage 3 to 5 non-dialysis dependent chronic kidney disease.  In
addition, Keryx's Japanese partner, Japan Tobacco Inc. and Torii Pharmaceutical
Co., Ltd. has filed its New Drug Application for marketing approval of ferric
citrate in  Japan  for the treatment of hyperphosphatemia in patients with
chronic kidney disease.  Keryx is headquartered in New York City.   

KERYX CONTACT:
Lauren Fischer
Director - Investor Relations
Keryx Biopharmaceuticals, Inc.
Tel: 212.531.5965
E-mail:  lfischer@keryx.com

SOURCE  Keryx Biopharmaceuticals, Inc.

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.